GIP and obesity due to melanocortin 4 receptor deficiency: While GIP antibodies such as GIPg013 have been developed primarily as a research tool to assess the biological roles and actions of native GIP (Ravn et al. 2013, Table 1), others have been investigated as potential pharmacological interventions in obesity.